Skip to content
The Nexus
BUSINESSJul 16 · 03:03 UTCSCMP WORLDJulie Zhang

Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals

Mainland Chinese institutional fund managers have increased investments in Hong Kong-listed biotechnology stocks due to attractive valuations and a surge in cross-border licensing deals. E Fund Management, China's largest mutual fund manager, acquired a 7% stake in Biocytogen Pharmaceuticals by purchasing 91,500 shares at HK$46.90 each.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
E Fund ManagementorganizationBiocytogen Pharmaceuticalsorganizationmainland ChinaplaceHong Kongplacebiotechnologytopicgene-editingtopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting